{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cerebral-palsy/prescribing-information/baclofen/","result":{"pageContext":{"chapter":{"id":"a1f8af81-362f-5da7-9166-0fde1e964bc0","slug":"baclofen","fullItemName":"Baclofen","depth":2,"htmlHeader":"<!-- begin field 6ad1ddd6-289f-4864-bbb7-aa0600b1089e --><h2>Baclofen</h2><!-- end field 6ad1ddd6-289f-4864-bbb7-aa0600b1089e -->","summary":"","htmlStringContent":"<!-- begin item 5f09786e-21cc-4487-801e-aa0600b1089e --><!-- end item 5f09786e-21cc-4487-801e-aa0600b1089e -->","topic":{"id":"cb080700-b809-5879-ba1c-4734226ab00f","topicId":"0f1011cb-425e-4af4-96bc-aa0600b1059f","topicName":"Cerebral palsy","slug":"cerebral-palsy","lastRevised":"Last revised in June 2019","chapters":[{"id":"2c97cf22-ded7-5f6b-9971-01fa96e34742","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"199a5d03-ed79-5a2f-98f6-b2957bcb8e98","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4beff83c-dbfa-5637-b784-ebf8ff3588cb","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"dbe5efff-8172-5718-a5c7-dc541fceaf89","slug":"changes","fullItemName":"Changes"},{"id":"9a469f88-c893-5796-9d0a-7fae1d29ea46","slug":"update","fullItemName":"Update"}]},{"id":"4377ee38-3a9b-5372-b6dd-1f61066abb6f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"00a993ca-5a58-595b-a2ae-71e6bd0a4d5a","slug":"goals","fullItemName":"Goals"},{"id":"b2f18eae-4cd0-5e76-afee-943fd5d27473","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b62686c1-ae56-5bc6-bde4-b081b3426c3c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"0d458c8d-1e7b-54fd-a524-3b5a0e7674a4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9e93039d-84e2-5f74-968a-8af573f4329e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c167edc4-1191-5ca7-9db6-087246879ef0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f3f9c00f-4538-52e0-a35e-3716c7f44d4c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"fd44bf28-1217-5074-b45a-fb1c5bca82f9","slug":"definition","fullItemName":"Definition"},{"id":"ae4cb772-bdb9-5c12-821c-581a838fc7ea","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"282a3015-39e2-584a-81d5-827a77c3c78b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d39d348a-f8e8-5d79-9f4e-a4bb777547b0","slug":"causes","fullItemName":"Causes"},{"id":"d966fa98-6c15-5a78-b206-cff0859281b3","slug":"complications-comorbidities","fullItemName":"Complications and comorbidities"},{"id":"ca8f76b2-bce9-5a8f-b303-c6436438957b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"fe9f8832-f63d-5ccd-b070-c7ba31f70b7d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"59b79593-b32c-5d57-b3b1-0f6417d92e19","slug":"when-should-i-suspect-cerebral-palsy","fullItemName":"When should I suspect cerebral palsy?"}]},{"id":"a01dc7a0-fa94-542d-956a-a22ecf35c88c","fullItemName":"Management","slug":"management","subChapters":[{"id":"179edd74-69be-537a-aa3c-2c4b7bccb4f3","slug":"suspected-cerebral-palsy","fullItemName":"Scenario: Suspected cerebral palsy"},{"id":"dd20c5b6-9623-557e-bc6a-7a12784b31b4","slug":"child-with-confirmed-cerebral-palsy","fullItemName":"Scenario: Child with confirmed cerebral palsy"},{"id":"9d76ad07-23c6-557f-b5ae-515902b3b995","slug":"adult-with-confirmed-cerebral-palsy","fullItemName":"Scenario: Adult with confirmed cerebral palsy"}]},{"id":"ed850470-21de-51c7-b4b5-114c39c8beb9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a1f8af81-362f-5da7-9166-0fde1e964bc0","slug":"baclofen","fullItemName":"Baclofen"}]},{"id":"56cfe1ad-ad75-5c05-bd08-76cec8dc7ef4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f25e6923-7913-5f8d-8d85-13818a914ba3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"55ef2ad7-3634-5d2a-a482-d061dcc25d9e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9f6f7828-3fb4-52a5-81cf-c6914f24d426","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"32bf6060-9093-5ad6-a7bd-bbcabcbceae6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fba76f52-f4e1-52d0-b54f-86adb0434d68","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7f366f6a-54ad-5ddf-a1d9-d03acf753fcd","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"dc87b857-6959-524f-b91b-9f14f79e5e01","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ed850470-21de-51c7-b4b5-114c39c8beb9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a0ccb9e8-9313-5f1f-a08e-7cdd8ba6c7c1","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 3ea72798-c86c-42ba-9dfe-aa6d016621b2 --><h3>Contraindications and cautions</h3><!-- end field 3ea72798-c86c-42ba-9dfe-aa6d016621b2 -->","summary":"","htmlStringContent":"<!-- begin item 6058bf9a-0d8d-4787-9d3c-aa6d0166216e --><!-- begin field 41bd59e6-c86f-4d69-a2a5-aa6d016621b2 --><ul><li><strong>Do not prescribe baclofen to people with:</strong><ul><li>Rare hereditary conditions of porphyria, galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.</li><li>Active peptic ulceration.</li></ul></li><li><strong>Prescribe baclofen with caution to people:</strong><ul><li>With cerebrovascular disease.</li><li>With Parkinson's disease.</li><li>With respiratory, hepatic, or renal impairment.</li><li>With a history of peptic ulceration.</li><li>With bladder sphincter hypertonia.</li><li>With epilepsy.</li><li>With severe psychiatric disorders — may be exacerbated by baclofen.</li><li>Taking certain <a class=\"topic-reference internal-reference\" href=\"/topics/cerebral-palsy/prescribing-information/baclofen/#drug-interactions\">other drugs</a>.</li></ul></li><li><strong>Pregnancy:</strong> the manufacturer advises use only if the potential benefit outweighs risk as studies in animals have shown reproductive toxicity.</li><li><strong>Driving and using machinery:</strong> baclofen may cause drowsiness and may affect performance of skilled tasks (such as driving). The effects of alcohol are enhanced.</li><li><strong>Symptoms that may occur on abrupt withdrawal include: </strong>anxiety, confusional states, psychosis, convulsions, tachycardia, and temporary aggravation of spasticity.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cerebral-palsy/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cerebral-palsy/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 41bd59e6-c86f-4d69-a2a5-aa6d016621b2 --><!-- end item 6058bf9a-0d8d-4787-9d3c-aa6d0166216e -->","subChapters":[]},{"id":"f6b65aa6-2620-5dd7-9022-3b42b0b6fac2","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 437d659d-58b5-4cb8-8a55-aa6d0166303e --><h3>Adverse effects</h3><!-- end field 437d659d-58b5-4cb8-8a55-aa6d0166303e -->","summary":"","htmlStringContent":"<!-- begin item 271b4b1f-8eef-4a59-98a8-aa6d01662ff3 --><!-- begin field ccbaa201-5e86-4418-95d4-aa6d0166303e --><ul><li><strong>The most commonly reported adverse effects of baclofen are drowsiness and nausea.</strong><ul><li>These occur mainly at the start of treatment, often if the dose is increased too rapidly. They are often transitory and may be eased by reducing the dose.</li></ul></li><li><strong>Other common adverse effects include:</strong> confusion, constipation, depression, diarrhoea, dizziness, dry mouth; euphoria, hallucination, headache, hyperhidrosis, hypotension, paraesthesia, skin reactions, urinary disorders, vision disorders, and vomiting</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cerebral-palsy/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cerebral-palsy/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field ccbaa201-5e86-4418-95d4-aa6d0166303e --><!-- end item 271b4b1f-8eef-4a59-98a8-aa6d01662ff3 -->","subChapters":[]},{"id":"1515ea2c-4292-5b27-932c-a1eace988a48","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 9e58965a-389f-4d0c-b259-aa6d01663c56 --><h3>Drug interactions</h3><!-- end field 9e58965a-389f-4d0c-b259-aa6d01663c56 -->","summary":"","htmlStringContent":"<!-- begin item 4758ac67-daa5-4640-b3c6-aa6d01663c19 --><!-- begin field 929c85f1-4bdd-46e4-8aa4-aa6d01663c56 --><p><strong>Key drug interactions with baclofen include:</strong></p><ul><li>Alcohol, anxiolytics and hypnotics — may exacerbate the drowsiness effects of baclofen.</li><li>Tricyclic antidepressants — can enhance the muscle relaxant effects of baclofen, resulting in profound muscle hypotonia. Tricyclic antidepressants can also cause drowsiness which may be additive when taking baclofen.</li><li>Antihypertensives and diuretics — may potentiate the hypotensive effect of baclofen. It may be necessary to adjust doses of antihypertensive drugs.</li><li>Dopaminergics — there are reports of hallucination, confusion, headache and nausea in people with parkinsonism shortly after baclofen was added to their medication.</li><li>Lithium — people taking both lithium and baclofen should be monitored for severe aggravation of hyperkinetic symptoms, especially in people with Huntington's chorea.</li><li>Memantine — may modify the effects of baclofen.</li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) — may decrease excretion of baclofen.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cerebral-palsy/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cerebral-palsy/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 929c85f1-4bdd-46e4-8aa4-aa6d01663c56 --><!-- end item 4758ac67-daa5-4640-b3c6-aa6d01663c19 -->","subChapters":[]},{"id":"9b4d79e9-d170-5414-aa33-c0d9c90121b6","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field af488a8e-6695-4dee-8900-aa6d016645a8 --><h3>Dosage</h3><!-- end field af488a8e-6695-4dee-8900-aa6d016645a8 -->","summary":"","htmlStringContent":"<!-- begin item 99ab2633-d633-4f73-9243-aa6d0166456d --><!-- begin field 0759785b-03d2-4244-8b57-aa6d016645a8 --><ul><li>Enteral baclofen treatment should be started with a low dose that is gradually increased over about 4 weeks to achieve the optimum therapeutic effect.</li><li>Recommended dosing regimen for adults is initially 5 mg 3 times a day, gradually increased to a maintenance dose which is usually up to 60 mg daily in divided doses. Maximum dose is 100 mg per day.</li><li>Review treatment if no benefit within 6 weeks of achieving maximum dose.</li><li>If eGFR less than 15 mL/minute/1.73 m<sup>2</sup>, there may be risk of toxicity—use smaller doses (e.g. 5 mg daily by mouth) and if necessary increase dosage interval.</li><li>When stopping baclofen,<strong> </strong>discontinue by gradual dose reduction over at least 1–2 weeks (longer if withdrawal symptoms occur).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cerebral-palsy/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cerebral-palsy/references/\">NICE, 2019</a>]</p><!-- end field 0759785b-03d2-4244-8b57-aa6d016645a8 --><!-- end item 99ab2633-d633-4f73-9243-aa6d0166456d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}